ClinicalTrials.gov posted results on 2026-08-04 for NCT04887870, a completed phase 2/3 study of nivolumab in advanced or metastatic solid malignancies. The record describes a 49-participant study of sitravatinib alone or with other anticancer therapies, including nivolumab and pembrolizumab.
Background
The trial enrolled participants with advanced or metastatic solid malignancies. Along with nivolumab, the intervention list included sitravatinib, pembrolizumab, enfortumab vedotin-ejfv, and ipilimumab.
Trial design
According to the posted record, this was a PHASE2/PHASE3 study with an overall status of COMPLETED. The brief title was Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study, and the brief summary described sitravatinib alone or in combination with other anticancer therapies in advanced or metastatic malignancies.
Key results
The posted results did not include primary outcome data, but they did list treatment-related adverse events across six parent-study groups. For one set of results, the counts were 6 participants, 4 participants, 13 participants, 3 participants, 21 participants, and 1 participant in Parent Studies 1 through 6, respectively.
A second set of posted counts for treatment-related adverse events showed 4 participants, 3 participants, 8 participants, 2 participants, 16 participants, and 1 participant across Parent Studies 1 through 6. No dispersion values, p-values, or confidence intervals were provided in the posted record.
What this means
These results add outcome reporting to a multi-drug oncology program that included nivolumab and pembrolizumab, but the available record is limited to treatment-related adverse event counts. Without primary endpoint data, the posting is most useful as a source document for trial tracking rather than for efficacy conclusions.
Source
This information is based on ClinicalTrials.gov results posted for NCT04887870 on 2026-08-04. The record is available at clinicaltrials.gov.